TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating
JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38
UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35
Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
